Chapman RW, Varghese Z, Gaul R, et al.: Association of primary sclerosing cholangitis with HLA-B8. Gut 1983, 24:38–41.
Schrumpf E, Fausa O, Fore O, et al.: HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease. Scand J Gastroenterol 1982, 17:187–191.
Donaldson PT, Farrant JM, Wilkinson ML, et al.: Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis. Hepatology 1991, 13:129–133.
Seibold R, Weber P, Schoning A, et al.: Neutrophil antibodies (pANCA) in chronic liver disease: do they react with different antigens? Eur J Gastroenterol Hepatol 1996, 8:1095–1100.
Schrumpf E, Fausa O, Elgio K, et al.: Hepatobiliary complications of inflammatory bowel disease. Semin Liver Dis 1988, 8:201–209.
Wiesner RH, Grambsch PM, Dickson ER, et al.: Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989, 10:430–436.
Ludwig J, Barham SS, LaRusso NF, et al.: Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1981, 1:632–640.
Finegold MJ, Carpenter RJ: Obliterative cholangitis due to cytomegalovirus: a possible precursor of paucity of intrahepatic bile ducts. Hum Pathol 1982, 13:662–665.
Holzbach RT, Marsh ME, Freedman MR, et al.: Portal vein bile acids in patients with severe inflammatory bowel disease. Gut 1980, 21:428–435.
Dew MJ, van Berge Henegouwen GP, Huybregts AW, et al.: Hepatotoxic effect of bile acids in inflammatory bowel disease. Gastroenterology 1980, 78:1393–1401.
Gross JB Jr, Ludwig J, Wiesner RH, et al.: Abnormalities in tests of copper metabolism in primary sclerosing cholangitis. Gastroenterology 1985, 89:272–278.
Bergquist A, Broomé U: Clinical features in primary sclerosing cholangitis. Clin Liver Dis 1998, 2:283–301.
Brandt DJ, MacCarty RL, Charboneau JW, et al.: Gallbladder disease in patients with primary sclerosing cholangitis. Am J Roentgenol 1988, 150:571–574.
Aadland E, Schrumpf E, Fausa O, et al.: Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol 1997, 22:655–664.
Farrant JM, Hayllar KM, Wilkinson ML, et al.: Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991, 100:1710–1717.
Rosen CB, Nagorney DM: Cholangiocarcinoma complicating primary sclerosing cholangitis. Semin Liver Dis 1991, 11:26–30.
Broomé U, Olsson R, Loof L, et al.: Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996, 38:610–615. In this study, 305 patients with PSC were followed for a median of 63 months. Multivariate analyses were used to evaluate key end points, including liver transplantation, development of cholangiocarcinoma, and death.
Carson KL, Tran TT, Cotton P, et al.: Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Am J Gastroenterol 1996, 91:1022–1023.
Bohorfoush A, Franco J, Komorowski R, et al.: Flow cytometric analysis of bile duct epithelium in primary sclerosing cholangitis potentially assists timing of liver transplantation. Gastrointest Endosc 1997, 45:1858A.
Lindor KD, for the Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group: Urosodiol for primary sclerosing cholangitis. N Engl J Med 1997, 336:691–695. This randomized double-blind study evaluated the effectiveness of UDCA in the treatment of PSC. End points addressed included biochemical, histologic, and clinical deterioration; the need for liver transplantation; and death.
Stiehl A, Walker S, Stiehl L, et al.: Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis: a 30 year pilot study with a placebo-controlled study period. J Hepatol 1994, 20:57–64.
Olsson R, Broomé U, Danielsson A, et al.: Colchicine treatment of primary sclerosing cholangitis. Gastroenterology 1995, 108:1199–1203.
LaRusso NF, Wiesner RH, Ludwig J, et al.: Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 1988, 95:1036–1042.
Knox TA, Kaplan MM: A double-blind controlled trial of oralpulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994, 106:494–499.
Lindor KD, Wiesner RH, Colwell LJ: The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am J Gastroenterol 1991, 85:57–61.
Kyokane K, Ichihara T, Horisawa M, et al.: Successful treatment of primary sclerosing cholangitis with cyclosporine and corticosteroid. Hepatogastroenterology 1994, 41:449–452.
Van Thiel DH, Carroll P, Abu-Elmagd K, et al.: Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995, 90:455–459.
Wiesner RH, Brambsch PM, Dickson ER, et al.: Primary sclerosing cholangitis: natural history, prognostic factors, and survival analysis. Hepatology 1989, 10:430–436.
Dickson ER, Murtaugh PA, Wiesner RH, et al.: Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 1992, 103:1893–1901.
Farrant JM, Hayllar KM, Wilkinson ML, et al.: Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991, 100:1710–1717.
Neuberger J: Recurrence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis. Liver Transplant Surg 1995, 1(suppl 5):109–115.
Metcalf J, Howel D, James O, et al.: Primary biliary cirrhosis: epidemiology helping the clinician. BMJ 1996, 312:1181–1182.
Witt-Sullivan H, Heathcote EJ, Cauch K, et al.: The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology 1990, 12:98–105.
Bach N, Schaffner F: Familial primary biliary cirrhosis. J Hepatol 1994, 20:698–701.
Cauch-Dudek K, Abbey S, Stewart DE, et al.: Fatigue and quality of life in primary biliary cirrhosis. Hepatology 1995, 22:108A.
Crippin JF, Lindor KD, Jorgensen R, et al.: Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk? Hepatology 1992, 15:858–862.
Navasa M, Pares A, Brugera M, et al.: Portal hypertension in primary biliary cirrhosis: relationship with histological features. J Hepatol 1987, 5:292–298.
Melia WM, Johnson PJ, Neuberger J, et al.: Hepatocellular carcinoma in primary biliary cirrhosis: detection by alphafetoprotein estimation. Gastroenterology 1984, 87:660–663.
Gershwin ME, Mackay IR, Sturgess A, et al.: Identification and specificity of a cDNA encoding the 70-kDa mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 1987, 138:3525–3531.
Yeaman SJ, Fussey SPM, Danner DJ, et al.: Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. Lancet 1988, 1:1067–1070.
Heathcote EJ: The clinical expression of primary biliary cirrhosis. Semin Liver Dis 1996, 17:23–33. The author presents a concise review of the clinical presentation of primary biliary cirrhosis and its associated extrahepatic disorders.
Scheuer PJ: Primary biliary cirrhosis. Proc R Soc Med 1967, 60:1257–1260.
Ludwig J, Dickson ER, McDonald GSA: Staging of chronic non-suppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch 1978, 379:103–112.
Shapiro J, Smith H, Schaffner F: Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 1979, 20:137–140.
Neuberger JM, Gunson BK, Buckels JAC, et al.: Referral of patients with primary biliary cirrhosis for liver transplantation. Gut 1990, 31:1069–1072.
Dickson ER, Grambsch PM, Fleming TR, et al.: Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989, 10:1–7.
Rydning A, Schrumpf E, Abdelnoor M, et al.: Factors of prognostic importance in primary biliary cirrhosis. Scand J Gastroenterol 1990, 25:119–126.
Christensen E, Altman DG, Neuberger J, et al.: Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. Gastroenterology 1993, 105:1865–1876.
Kilmurry MR, Heathcote EJ, Cauch-Dudek K, et al.: Is the Mayo model for predicting survival useful after introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis? Hepatology 1996, 23:1148–1153.
Poupon RE, Lindor KD, Cauch-Dudek K, et al.: Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997, 113:884–890. This analysis of the combined data of three large trials of UDCA therapy in patients with PBC demonstrates that long-term UDCA improves survival without liver transplantation in patients with moderate or severe disease.
Hendrickse M, Rigney E, Giaffer MH, et al.: Low-dose methotrexate in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Hepatology 1997, 26:248A.
Hubscher SG, Elias E, Buckels JAC, et al.: Primary biliary cirrhosis: histological evidence of disease recurrence after liver transplantation. J Hepatol 1993, 18:173–184.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.4